Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | CES2 | O00748 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 7/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883279 | 1.00 | EPHX1 (0.51) | EPHX1CES2CNR1CNR2LPAR1 | |
| SCHEMBL23613458 | 0.87 | CYP2D6 (0.38) | EPHX1CES2CNR1CNR2CYP2D6 | |
| SCHEMBL20883264 | 0.80 | EPHX1 (0.44) | EPHX1CES2CNR1CNR2LPAR1 | |
| SCHEMBL23613286 | 0.78 | PLA2G2C (0.35) | EPHX1CES2CYP2D6CYP2C19 | |
| SCHEMBL10683793 | 0.77 | CES2 (0.60) | EPHX1CES2LPAR1LPAR3FAAH | |
| SCHEMBL10685203 | 0.77 | CES2 (0.60) | EPHX1CES2LPAR1LPAR3FAAH | |
| SCHEMBL10688527 | 0.77 | CES2 (0.60) | EPHX1CES2LPAR1LPAR3FAAH | |
| SCHEMBL10690534 | 0.77 | CES2 (0.60) | EPHX1CES2LPAR1LPAR3FAAH | |
| SCHEMBL10689228 | 0.77 | CES2 (0.60) | EPHX1CES2LPAR1LPAR3FAAH | |
| SCHEMBL10684057 | 0.74 | CES2 (0.57) | EPHX1CES2LPAR1LPAR3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| WO-2019071093-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | ALK, ENPP2, CYSLTR2 | EPHX1 596/4885CES2 659/4885CNR1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.